Hormone therapy for obesity-linked endometrial cancer that didn't respond to progestin
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 1, Grade 1 endometrial cancer that hasn't spread into the uterus muscle wall or beyond.
- Your BMI is 30 or higher (obese).
- You have taken progestin hormone therapy (pills or hormonal IUD) as your first treatment, but it didn't fully work (cancer stayed the same after 7 months or didn't disappear after 10 months).
- You want to keep your uterus and ability to have children.
- You are willing to follow the treatment plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests adding orlistat to standard hormone therapy for people with early endometrial cancer or atypical hyperplasia who have not fully responded to initial hormone treatment. It aims to preserve fertility and avoid hysterectomy.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This trial tests combining a weight-loss medication (mazdutide) with a hormone-releasing intrauterine device (LNG-IUS) to treat early-stage uterine cancer or precancerous changes while preserving fertility. It aims to help patients who are overweight or obese and wish to avoid hysterectomy.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.